HRP20171106T1 - 5-supstituirani kinazolinonski derivati kao sredstva protiv raka - Google Patents
5-supstituirani kinazolinonski derivati kao sredstva protiv raka Download PDFInfo
- Publication number
- HRP20171106T1 HRP20171106T1 HRP20171106TT HRP20171106T HRP20171106T1 HR P20171106 T1 HRP20171106 T1 HR P20171106T1 HR P20171106T T HRP20171106T T HR P20171106TT HR P20171106 T HRP20171106 T HR P20171106T HR P20171106 T1 HRP20171106 T1 HR P20171106T1
- Authority
- HR
- Croatia
- Prior art keywords
- disease
- disorder
- image
- compound
- halo
- Prior art date
Links
- -1 5-substituted quinazolinone Chemical class 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 21
- 208000035475 disorder Diseases 0.000 claims 19
- 125000001475 halogen functional group Chemical group 0.000 claims 19
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 17
- 201000010099 disease Diseases 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 208000002193 Pain Diseases 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 208000002780 macular degeneration Diseases 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 5
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 5
- 208000019693 Lung disease Diseases 0.000 claims 5
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 5
- 230000033115 angiogenesis Effects 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 239000010425 asbestos Substances 0.000 claims 5
- 229910052895 riebeckite Inorganic materials 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 208000030852 Parasitic disease Diseases 0.000 claims 4
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 4
- 208000015114 central nervous system disease Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 4
- 208000017520 skin disease Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 3
- 206010020649 Hyperkeratosis Diseases 0.000 claims 3
- 208000001294 Nociceptive Pain Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 230000007812 deficiency Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims 3
- 208000001387 Causalgia Diseases 0.000 claims 2
- 206010010099 Combined immunodeficiency Diseases 0.000 claims 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 2
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 2
- 208000012609 Cowden disease Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000001126 Keratosis Diseases 0.000 claims 2
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010035600 Pleural fibrosis Diseases 0.000 claims 2
- 206010067284 Pulmonary arteriopathy Diseases 0.000 claims 2
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000028831 congenital heart disease Diseases 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 208000034737 hemoglobinopathy Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 206010021198 ichthyosis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010000591 Acrochordon Diseases 0.000 claims 1
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000004881 Amebiasis Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 206010001980 Amoebiasis Diseases 0.000 claims 1
- 206010002064 Anaemia macrocytic Diseases 0.000 claims 1
- 241001465677 Ancylostomatoidea Species 0.000 claims 1
- 206010058079 Anomalous pulmonary venous connection Diseases 0.000 claims 1
- 208000033116 Asbestos intoxication Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010003598 Atelectasis Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010068975 Bone atrophy Diseases 0.000 claims 1
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010064012 Central pain syndrome Diseases 0.000 claims 1
- 206010008334 Cervicobrachial syndrome Diseases 0.000 claims 1
- 208000009043 Chemical Burns Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 208000029147 Collagen-vascular disease Diseases 0.000 claims 1
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 claims 1
- 208000034656 Contusions Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000008953 Cryptosporidiosis Diseases 0.000 claims 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 claims 1
- 206010061802 Cyclosporidium infection Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010063045 Effusion Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000037487 Endotoxemia Diseases 0.000 claims 1
- 208000031213 Epidermal nevus syndrome Diseases 0.000 claims 1
- 208000017347 Erythrokeratoderma Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010016675 Filariasis lymphatic Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000031797 Harlequin ichthyosis Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- 206010021133 Hypoventilation Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 208000007924 IgA Deficiency Diseases 0.000 claims 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 206010023076 Isosporiasis Diseases 0.000 claims 1
- 208000001913 Lamellar ichthyosis Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 208000037263 Lymphatic filariasis Diseases 0.000 claims 1
- 206010026673 Malignant Pleural Effusion Diseases 0.000 claims 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 201000000090 Microsporidiosis Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 201000009053 Neurodermatitis Diseases 0.000 claims 1
- 201000008962 Nezelof syndrome Diseases 0.000 claims 1
- 206010029412 Nightmare Diseases 0.000 claims 1
- 241001631646 Papillomaviridae Species 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034487 Pericarditis constrictive Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010035592 Pleural calcification Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 claims 1
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 208000009527 Refractory anemia Diseases 0.000 claims 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 241000242678 Schistosoma Species 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 206010039915 Selective IgA immunodeficiency Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000028990 Skin injury Diseases 0.000 claims 1
- 206010040954 Skin wrinkling Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010041235 Snoring Diseases 0.000 claims 1
- 206010041347 Somnambulism Diseases 0.000 claims 1
- 206010042254 Strongyloidiasis Diseases 0.000 claims 1
- 208000012827 T-B+ severe combined immunodeficiency due to gamma chain deficiency Diseases 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 206010053615 Thermal burn Diseases 0.000 claims 1
- 208000001435 Thromboembolism Diseases 0.000 claims 1
- 208000002715 Thymic aplasia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 206010044269 Toxocariasis Diseases 0.000 claims 1
- 201000005485 Toxoplasmosis Diseases 0.000 claims 1
- 206010044608 Trichiniasis Diseases 0.000 claims 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 claims 1
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 claims 1
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 claims 1
- 201000007146 X-linked severe combined immunodeficiency Diseases 0.000 claims 1
- 201000010272 acanthosis nigricans Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 claims 1
- 208000019269 advanced heart failure Diseases 0.000 claims 1
- 201000008907 algoneurodystrophy Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010002906 aortic stenosis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 206010003441 asbestosis Diseases 0.000 claims 1
- 201000009361 ascariasis Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 claims 1
- 201000001286 autosomal recessive congenital ichthyosis 4B Diseases 0.000 claims 1
- 201000008680 babesiosis Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 230000005796 circulatory shock Effects 0.000 claims 1
- 230000009852 coagulant defect Effects 0.000 claims 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 208000000839 constrictive pericarditis Diseases 0.000 claims 1
- 230000009519 contusion Effects 0.000 claims 1
- 201000002641 cyclosporiasis Diseases 0.000 claims 1
- 201000008167 cystoisosporiasis Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 201000010307 dermatosis papulosa nigra Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 208000005239 filarial elephantiasis Diseases 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 201000006592 giardiasis Diseases 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000018578 heart valve disease Diseases 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 201000002597 ichthyosis vulgaris Diseases 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 201000007156 immunoglobulin alpha deficiency Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 201000006437 macrocytic anemia Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 201000009969 melanoacanthoma Diseases 0.000 claims 1
- 201000011475 meningoencephalitis Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000008588 molluscum contagiosum Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000003040 nociceptive effect Effects 0.000 claims 1
- 208000003154 papilloma Diseases 0.000 claims 1
- 208000029211 papillomatosis Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000003619 porokeratosis Diseases 0.000 claims 1
- 208000017940 prurigo nodularis Diseases 0.000 claims 1
- 210000001147 pulmonary artery Anatomy 0.000 claims 1
- 208000037813 pulmonary venous hypertension Diseases 0.000 claims 1
- 230000011514 reflex Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 201000007153 reticular dysgenesis Diseases 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 239000000790 retinal pigment Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims 1
- 208000029138 selective IgA deficiency disease Diseases 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 201000000195 skin tag Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 230000036575 thermal burns Effects 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 208000003982 trichinellosis Diseases 0.000 claims 1
- 201000007588 trichinosis Diseases 0.000 claims 1
- 208000001729 trichostasis spinulosa Diseases 0.000 claims 1
- 208000009920 trichuriasis Diseases 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 201000002311 trypanosomiasis Diseases 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Claims (21)
1. Spoj s formulom (II):
[image]
ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer naznačen time da je za uporabu u postupku za liječenje, upravljanje ili prevenciju bolesti ili poremećaja, pri čemu bolest ili poremećaj je bolest ili poremećaj povezan s neželjenom angiogenezom; bol; makularna degeneracija; kožna bolest; plućni poremećaj; poremećaj vezan uz azbest; parazitska bolest; poremećaj imunodeficijencije; CNS poremećaj; ateroskleroza; disfunkcionalni san; ili hemoglobinatija, pri čemu:
R4 je: vodik; halo; -(CH2)nOH; (C1-C6)alkil, proizvoljno supstituiran s jednim ili više halo; ili
(C1-C6)alkoksi, proizvoljno supstituiran s jednim ili više halo;
R5 je: vodik; -(CH2)nOH; fenil; -O-(C1-C6)alkil; ili (C1-C6)alkil, proizvoljno supstituiran s jednim ili više halo;
R6 je: vodik; ili (C1-C6)alkil, proizvoljno supstituiran s jednim ili više halo; i
n je 0, 1, ili 2.
2. Spoj za uporabu prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer,
naznačen time da R4 je metil ili metoksi; ili
pri čemu R4 je F ili Cl; ili
pri čemu R4 je -CF3.
3. Spoj za uporabu prema zahtjevu 1, naznačen time da je:
[image]
[image]
[image]
[image]
[image]
[image]
ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer.
4. Spoj s formulom (III):
[image]
ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer naznačen time da je za uporabu u postupku za liječenje, upravljanje ili prevenciju bolesti ili poremećaja, pri čemu bolest ili poremećaj je bolest ili poremećaj povezan s neželjenom angiogenezom; bol; makularna degeneracija; kožna bolest; plućni poremećaj; poremećaj vezan uz azbest; parazitska bolest; poremećaj imunodeficijencije; CNS poremećaj; ateroskleroza; disfunkcionalni san; ili hemoglobinatija, pri čemu:
Rd je: vodik;
(C1-C6)alkil, proizvoljno supstituiran s jednim ili više halo;
-C(O)-(C1-C8)alkil, pri čemu je alkil proizvoljno supstituiran s jednim ili više halo;
-C(O)-(CH2)n-(C3-C10-cikloalkil);
-C(O)-(CH2)n-NReRf, pri čemu Re i Rf su svaki neovisno:
vodik;
(C1-C6)alkil, proizvoljno supstituiran s jednim ili više halo; ili
(C1-C6)alkoksi, proizvoljno supstituiran s jednim ili više halo; ili
-C(O)-(CH2)n-O-(C1-C6)alkil.
R7 je: vodik; -(CH2)nOH; fenil; -O-(C1-C6)alkil; ili (C1-C6)alkil, proizvoljno supstituiran s jednim ili više halo;
R8 je: vodik; ili (C1-C6)alkil, proizvoljno supstituiran s jednim ili više halo; i
n je 0, 1, ili 2.
5. Spoj za uporabu prema zahtjevu 4, ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer,
naznačen time da R7 je metil; ili
pri čemu Rd je -C(O)-(C1-C6)alkil; ili
pri čemu Rd je -C(O)-CH2-O-(C1-C6)alkil.
6. Spoj za uporabu prema zahtjevu 4, naznačen time da je:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer.
7. Spoj za uporabu prema zahtjevu 6, naznačen time da je:
[image]
ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer.
8. Spoj s formulom (IV):
[image]
ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer naznačen time da je za uporabu u postupku za liječenje, upravljanje ili prevenciju bolesti ili poremećaja, pri čemu bolest ili poremećaj je bolest ili poremećaj povezan s neželjenom angiogenezom; bol; makularna degeneracija; kožna bolest; plućni poremećaj; poremećaj vezan uz azbest; parazitska bolest; poremećaj imunodeficijencije; CNS poremećaj; ateroskleroza; disfunkcionalni san; ili hemoglobinatija, pri čemu:
Rg je: -(CH2)n-(6 do 10 člani aril);
-C(O)-(CH2)n-(6 do 10 člani aril) ili -C(O)-(CH2)n-(6 do 10 člani heteroaril),
pri čemu je aril ili heteroaril proizvoljno supstituiran s jednim ili više od: halo; -SCF3; (C1-C6)alkil, sam za sebe proizvoljno supstituiran s jednim ili više halo; ili (C1-C6)alkoksi, sam za sebe proizvoljno supstituiran s jednim ili više halo; -C(O)-(CH2)n-NHRh, pri čemu Rh je:
6 do 10 člani aril, proizvoljno supstituiran s jednim ili više od: halo; (C1-C6)alkil, sam za sebe proizvoljno supstituiran s jednim ili više halo; ili (C1-C6)alkoksi, sam za sebe proizvoljno supstituiran s jednim ili više halo; ili -C(O)-(CH2)n-O-(CH2)n-(6 do 10 člani aril);
R9 je: vodik; -(CH2)nOH; fenil; -O-(C1-C6)alkil; ili (C1-C6)alkil, proizvoljno supstituiran s jednim ili više halo;
R10 je: vodik; ili (C1-C6)alkil, proizvoljno supstituiran s jednim ili više halo; i
n je 0, 1, ili 2.
9. Spoj za uporabu prema zahtjevu 8,
naznačen time da R9 je metil; ili
pri čemu Rg je -C(O)-fenil, -C(O)-CH2-fenil, ili -C(O)-NH-fenil; proizvoljno pri čemu je fenil supstituiran s jednim ili više od metila, -CF3, ili halogena.
10. Spoj za uporabu prema zahtjevu 8, naznačen time da je:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer.
11. Spoj za uporabu prema bilo kojem od zahtjeva 1-10, naznačen time da bolest ili poremećaj povezan s neželjenom angiogenezom je upalna bolest, autoimuna bolest, virusna bolest, genetska bolest, alergijska bolest, bakterijska bolest, očna neovaskularna bolest, koroidalna neovaskularna bolest, neovaskularna bolest retine ili rubeoza; ili
pri čemu bolest ili poremećaj povezan s neželjenom angiogenezom je artritis, endometrioza, Crohnova bolest, zatajenje srca, uznapredovalo zatajenje srca, oštećenje bubrega, endotoksemija, sindrom toksičnog šoka, osteoartritis, replikacija retrovirusa, slabljenje, meningitis, fibroza izazvana silicijem, fibroza izazvana azbestom, veterinarski poremećaj, hiperkalcemija povezana s malignitetom, moždani udar, cirkulacijski šok, parodontitis, gingivitis, makrocitna anemija, refraktorna anemija ili 5q-delecijski sindrom.
12. Spoj za uporabu prema bilo kojem od zahtjeva 1-10, naznačen time da bol je nociceptivna bol, neuropatska bol, miješana bol nociceptivne i neuropatske boli, visceralna bol, migrena, glavobolja ili postoperativna bol; proizvoljno pri čemu
nociceptivna bol je bol povezana s kemijskim ili toplinskim opeklinama, ozljedama kože, kontuzijama kože, osteoartritis, reumatoidni artritis, tendonitis, i miofascijalna bol;
neuropatska bol je CRPS tip I, CRPS tip II, refleksna simpatička distrofija (RSD), refleksna neurovaskularna distrofija, refleksna distrofija, simpatički održavana bolni sindrom, kauzalgija, Sudeckova atrofija kostiju, algoneurodistrofija, sindrom rame-šaka, posttraumatska distrofija, trigeminalna neuralgija, post herpesna neuralgija, bol povezana s rakom, fantomska bol u udovima, fibromijalgija, sindrom kroničnog umora, ozljeda leđne moždine, središnja bol nakon moždanog udara, radikulopatija, dijabetička neuropatija, bol nakon moždanog udara ili luetička neuropatija.
13. Spoj za uporabu prema bilo kojem od zahtjeva 1-10, naznačen time da makularna degeneracija (MD) ili srodni sindrom je atrofijska (suha) MD, eksudativna (vlažna) MD, makulopatija vezana uz dob (ARM), koroidalna neovaskularizacija (CNVM), odvajanje epitela retinalnog pigmenta (PED) ili atrofija epitela retinalnog pigmenta (RPE).
14. Spoj za uporabu prema bilo kojem od zahtjeva 1-10, naznačen time da kožna bolest je keratoza ili srodni simptom, infekcija povezana s papiloma virusom, arsenske keratoze, Leser-Trélatov znak, bradavičasti diskeratom, trichostasis spinulosa, varijabilna eritrokeratodermija, fetalna ihtioza (harlekin ihtioza), kožni jastučići prstiju, kožni melanoakantom, porokeratoza, psorijaza, karcinom skvamoznih stanica, konfluentna i retikularna papilomatoza, akrokordoni, kožni rog, Cowdenova bolest (multipli hamartoma sindrom), dermatosis papulosa nigra, sindrom epidermalnog nevusa, ihtioza vulgaris, molluscum contagiosum, prurigo nodularis, acanthosis nigricans, akne ili bore.
15. Spoj za uporabu prema bilo kojem od zahtjeva 1-10, naznačen time da plućni poremećaj je primarna plućna hipertenzija (PPH); sekundarna plućna hipertenzija; obiteljska PPH; sporadična PPH; prekapilarna plućna hipertenzija; plućna arterijska hipertenzija; hipertenzija plućne arterije; idiopatska plućna hipertenzija; trombozna plućna arteriopatija; pleksogena plućna arteriopatija; plućna hipertenzija funkcionalnih razreda I do IV; ili plućna hipertenzija povezana s disfunkcijom lijeve klijetke, bolest srčanih zalistaka, konstriktivni perikarditis, stenoza aorte, kardiomiopatija, medijastinalna fibroza, anomalna plućna venska drenaža, plućna venookluzivna bolest, kolagena vaskularna bolest, urođena srčana bolest, infekcija HIV virusom, kongenitalna bolest srca, plućna venska hipertenzija, kronična opstruktivna plućna bolest, intersticijska plućna bolest, poremećaj disanja u snu, alveolarni hipoventilacijski poremećaj, kronično izlaganje velikoj nadmorskoj visini, neonatalna plućna bolest, alveolarno-kapilarna displazija, bolest srpastih stanica, poremećaj koagulacije, kronična tromboembolija, bolest vezivnog tkiva, lupus, šistosomijaza, sarkoidoza ili plućna kapilarna hemangiomatoza.
16. Spoj za uporabu prema bilo kojem od zahtjeva 1-10, naznačen time da poremećaj povezan s azbestom je mezoteliom, azbestoza, maligni pleuralni izljev, benigni eksudativni izljev, pleuralni plakovi, pleuralna kalcifikacija, difuzna pleuralna zadebljanja, atelektaza, fibrozne mase ili rak pluća.
17. Spoj za uporabu prema bilo kojem od zahtjeva 1-10, naznačen time da parazitska bolest je malarija, babezioza, tripanosomijaza, lišmanijaza, toksoplazmoza, meningoencefalitis, keratitis, amebijaza, giardijaza, kriptosporidioza, izosporijaza, ciklosporijaza, mikrosporidioza, askarijaza, trihurijaza, ankilostomijaza, strongiloidijaza, toksokarijaza, trihinoza, limfatična filarijaza, ili dermatitis uzrokovan životinjskim shistosomama.
18. Spoj za uporabu prema bilo kojem od zahtjeva 1-10, naznačen time da poremećaj imunodeficijencije je nedostatak adenozin deaminaze, nedostatak antitijela s normalnim ili povišenim Igs, ataksija-tenlangiektazija, limfocitni sindrom, zajednička varijabilna imunodeficijencija, nedostatak Ig s hiper-IgM, delecija Ig teškog lanca, nedostatak IgA, imunodeficijencija s timomom, retikularna disgeneza, Nezelofov sindrom, selektivni nedostatak IgG podskupine, prolazne hipogamaglobulinemija od djetinjstva, Wiskott-Aldrichov sindrom, X-vezana agamaglobulinemija ili X-vezana teška kombinirana imunodeficijencija.
19. Spoj za uporabu prema bilo kojem od zahtjeva 1-10, naznačen time da CNS poremećaj je amiotrofna lateralna skleroza, Alzheimerova bolest, Parkinsonova bolest, Huntingtonova bolest, multipla skleroza, Touretteov sindrom, delirij, poremećaj svijesti, amnestični poremećaj, ili diskretno oštećenje pamćenja.
20. Spoj za uporabu prema bilo kojem od zahtjeva 1-10, naznačen time da disfunkcionalni san ili srodni sindrom je hrkanje, apneja za vrijeme spavanja, nesanica, narkolepsija, sindrom nemirnih nogu, noćne more, mjesečarenje, noćno jedenje ili disfunkcionalni san povezan s kroničnim neurološkim ili upalnim stanjem.
21. Spoj za uporabu prema bilo kojem od zahtjeva 1-10, naznačen time da hemoglobinatija ili srodni poremećaj je hemoglobinopatija ili anemija srpastih stanica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84747106P | 2006-09-26 | 2006-09-26 | |
EP11174059.3A EP2428513B1 (en) | 2006-09-26 | 2007-09-25 | 5-substituted quinazolinone derivatives as anti-cancer agents |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20171106T1 true HRP20171106T1 (hr) | 2017-10-06 |
Family
ID=39230813
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120447TT HRP20120447T1 (hr) | 2006-09-26 | 2012-05-24 | 5-supstituirani derivati kinazolinona kao protutumorska sredstva |
HRP20160266TT HRP20160266T1 (hr) | 2006-09-26 | 2016-03-14 | 5-supstituirani derivati kinazolinona kao sredstva protiv raka |
HRP20171093TT HRP20171093T1 (hr) | 2006-09-26 | 2017-07-17 | 5-supstituirani derivati kinazolina i sastavi koji ih sadrže i metode u kojima se koriste |
HRP20171106TT HRP20171106T1 (hr) | 2006-09-26 | 2017-07-18 | 5-supstituirani kinazolinonski derivati kao sredstva protiv raka |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120447TT HRP20120447T1 (hr) | 2006-09-26 | 2012-05-24 | 5-supstituirani derivati kinazolinona kao protutumorska sredstva |
HRP20160266TT HRP20160266T1 (hr) | 2006-09-26 | 2016-03-14 | 5-supstituirani derivati kinazolinona kao sredstva protiv raka |
HRP20171093TT HRP20171093T1 (hr) | 2006-09-26 | 2017-07-17 | 5-supstituirani derivati kinazolina i sastavi koji ih sadrže i metode u kojima se koriste |
Country Status (34)
Country | Link |
---|---|
US (4) | US7635700B2 (hr) |
EP (5) | EP3239144A1 (hr) |
JP (4) | JP5388854B2 (hr) |
KR (1) | KR101414786B1 (hr) |
CN (6) | CN105017212A (hr) |
AR (2) | AR063015A1 (hr) |
AT (1) | ATE555104T1 (hr) |
CA (1) | CA2663731C (hr) |
CL (1) | CL2007002752A1 (hr) |
CO (1) | CO6160323A2 (hr) |
CR (1) | CR10712A (hr) |
CY (3) | CY1112860T1 (hr) |
DK (4) | DK2428513T3 (hr) |
ES (4) | ES2564935T3 (hr) |
HK (1) | HK1167397A1 (hr) |
HR (4) | HRP20120447T1 (hr) |
HU (3) | HUE035389T2 (hr) |
IL (3) | IL197716A (hr) |
LT (2) | LT2428513T (hr) |
ME (4) | ME01421B (hr) |
MX (1) | MX2009003038A (hr) |
MY (1) | MY150699A (hr) |
NI (1) | NI200900040A (hr) |
NZ (1) | NZ575830A (hr) |
PE (1) | PE20080970A1 (hr) |
PL (4) | PL2420497T3 (hr) |
PT (3) | PT2428513T (hr) |
RS (3) | RS54607B1 (hr) |
RU (3) | RU2463298C2 (hr) |
SI (4) | SI2420497T1 (hr) |
TW (2) | TWI522351B (hr) |
UA (1) | UA94964C2 (hr) |
WO (1) | WO2008039489A2 (hr) |
ZA (1) | ZA200901950B (hr) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8877780B2 (en) * | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
DK2428513T3 (en) * | 2006-09-26 | 2017-08-21 | Celgene Corp | 5-substituted quinazolinone derivatives as anti-cancer agents |
US8354417B2 (en) * | 2007-09-26 | 2013-01-15 | Celgene Corporation | Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same |
CN104211684A (zh) * | 2007-09-26 | 2014-12-17 | 细胞基因公司 | 6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法 |
US7786171B2 (en) | 2008-04-04 | 2010-08-31 | Abbott Laboratories | Amide derivatives as positive allosteric modulators and methods of use thereof |
WO2009148623A2 (en) | 2008-06-05 | 2009-12-10 | Stc.Unm | Methods and related compositions for the treatment of cancer |
US20100160368A1 (en) | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
US20110021555A1 (en) | 2008-12-19 | 2011-01-27 | Graceway Pharmaceuticals, Llc | Lower dosage strength imiquimod formulations and shorter dosing regimens for treating actinic keratoses |
TWI546537B (zh) * | 2009-05-19 | 2016-08-21 | 維維亞生技公司 | 提供針對血液腫瘤之體外個人化藥物測試之方法 |
JP5645816B2 (ja) | 2009-05-25 | 2014-12-24 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
US20110207766A1 (en) | 2009-07-13 | 2011-08-25 | Graceway Pharmaceuticals, Llc. | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
CN101913846B (zh) * | 2010-08-11 | 2012-05-23 | 昆明理工大学 | 一种用煤泥磷石膏冶金废渣合成陶粒的方法 |
EP2683384B1 (en) * | 2011-03-11 | 2015-12-09 | Celgene Corporation | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
SG192946A1 (en) * | 2011-03-11 | 2013-09-30 | Celgene Corp | Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
WO2012135299A1 (en) | 2011-03-28 | 2012-10-04 | Deuteria Pharmaceuticals Inc | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
WO2012149299A2 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
ES2699810T3 (es) | 2012-06-29 | 2019-02-12 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando proteínas asociadas a cereblon |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
CN104755472A (zh) * | 2012-09-04 | 2015-07-01 | 细胞基因公司 | 3-(5-氨基-2-甲基-4-氧代喹唑啉-3(4h)-基)哌啶-2,6-二酮的同位素体及其制备方法 |
BR112015005243A2 (pt) * | 2012-09-10 | 2017-07-04 | Celgene Corp | métodos para o tratamento de câncer de mama localmente avançado |
CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
WO2014152833A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
AU2014253978B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and a 5-Substituted Quinazolinone Compound for treating cancer |
MX363652B (es) | 2013-05-01 | 2019-03-28 | Celgene Corp | Sintesis de 3-(5-amino-2-metil-4-oxoquinazolin-3(4h)-il)piperidin- 2,6-diona. |
JP2016521280A (ja) * | 2013-05-03 | 2016-07-21 | セルジーン コーポレイション | 併用療法を用いて癌を治療する方法 |
UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
CN103645259B (zh) * | 2013-12-12 | 2015-03-11 | 深圳海王药业有限公司 | 一种同时测定泊马度胺及其有关物质的方法 |
TW201540323A (zh) | 2014-01-15 | 2015-11-01 | Celgene Corp | 3-(5-胺基-2-甲基-4-側氧基-4h-喹唑啉-3-基)-哌啶-2,6-二酮之調配物 |
ES2747810T3 (es) | 2014-06-05 | 2020-03-11 | Bayer Cropscience Ag | Compuestos bicíclicos como agentes para combatir parásitos |
ES2843973T3 (es) | 2014-06-27 | 2021-07-21 | Celgene Corp | Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3 |
PL3182996T3 (pl) | 2014-08-22 | 2023-04-17 | Celgene Corporation | Sposoby leczenia szpiczaka mnogiego związkami immunomodulującymi w kombinacji z przeciwciałami |
TW201642857A (zh) | 2015-04-06 | 2016-12-16 | 西建公司 | 以組合療法治療肝細胞癌 |
EP3316888A1 (en) | 2015-07-02 | 2018-05-09 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
EA201890585A1 (ru) | 2015-08-27 | 2018-11-30 | Селджин Корпорейшн | Составы 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона |
US20180271849A1 (en) * | 2015-09-29 | 2018-09-27 | Kangpu Biopharmaceuticals, Ltd. | Pharmaceutical composition and application thereof |
CA3006758A1 (en) | 2015-12-02 | 2017-06-08 | Celgene Corporation | Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
JP6930748B2 (ja) | 2016-01-14 | 2021-09-01 | カンプ・バイオファーマスーティカルズ、リミテッドKangpu Biopharmaceuticals,Ltd | キナゾリン誘導体、そのための調製方法、医薬組成物、および適用 |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
KR102368555B1 (ko) | 2016-12-16 | 2022-02-28 | 강푸 바이오파마슈티칼즈 리미티드 | 조성물, 이의 적용 및 치료 방법 |
CA3053805C (en) | 2017-02-13 | 2020-06-30 | Kangpu Biopharmaceuticals, Ltd. | Combination treating prostate cancer, pharmaceutical composition and treatment method |
WO2018165142A1 (en) | 2017-03-07 | 2018-09-13 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
KR102014478B1 (ko) * | 2017-05-12 | 2019-08-26 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS |
JP7399846B2 (ja) | 2017-08-21 | 2023-12-18 | セルジーン コーポレイション | (s)-tert-ブチル4,5-ジアミノ-5-オキソペンタノエートの調製プロセス |
WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
EP3679027A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydrobenzimidazolones |
EP3679026A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
WO2019099868A2 (en) | 2017-11-16 | 2019-05-23 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
US11401336B2 (en) | 2018-02-21 | 2022-08-02 | Celgene Corporation | BCMA-binding antibodies and uses thereof |
JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー4 セラピューティクス, インコーポレイテッド | Ikarosの分解のためのセレブロン結合剤 |
WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
CA3130469A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
KR20220106801A (ko) | 2019-11-27 | 2022-07-29 | 캡터 테라퓨틱스 에스.에이. | 세레블론에 결합하는 피페리딘-2,6-디온 유도체 및 이의 사용 방법 |
JP2023504143A (ja) | 2019-11-27 | 2023-02-01 | キャプター セラピューティクス エス.エー. | セレブロンに結合するピペリジン-2,6-ジオン誘導体、及びその使用方法 |
WO2021168314A1 (en) * | 2020-02-21 | 2021-08-26 | Plexium, Inc. | Quinazolinone compounds and related compounds |
KR20230027082A (ko) | 2020-06-25 | 2023-02-27 | 셀진 코포레이션 | 조합 요법을 사용한 암의 치료 방법 |
WO2022029138A1 (en) | 2020-08-03 | 2022-02-10 | Captor Therapeutics S.A. | Low molecular weight protein degraders and their applications |
CA3189456A1 (en) * | 2020-08-14 | 2022-02-17 | Xiaobao Yang | Immunoregulatory compounds and anti-tumor application thereof |
WO2022146151A1 (en) | 2020-12-30 | 2022-07-07 | Captor Therapeutics S.A. | Novel compounds which bind to cereblon, and methods of use thereof |
WO2022255889A1 (en) | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
WO2022255890A1 (en) | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
WO2023151635A1 (zh) * | 2022-02-14 | 2023-08-17 | 标新生物医药科技(上海)有限公司 | 基于喹唑啉取代戊二酰亚胺骨架的化合物及其应用 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1997563A (en) * | 1929-05-31 | 1935-04-09 | Karmazin Engineering Company | Method of making heat radiators |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
ES2529190T3 (es) | 1996-07-24 | 2015-02-17 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-il)-ftalimidas sustituidas por amino para reducir los niveles de TNF-alfa |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
EP1343505A1 (en) | 2000-12-11 | 2003-09-17 | Tularik Inc. | Cxcr3 antagonists |
WO2003007955A2 (en) | 2001-07-20 | 2003-01-30 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
AU2002343220A1 (en) | 2001-11-09 | 2003-05-19 | Matsushita Electric Industrial Co., Ltd. | Moving picture coding method and apparatus |
FR2837201A1 (fr) * | 2002-03-18 | 2003-09-19 | Servier Lab | Nouveaux composes derives de la quinazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US20050024328A1 (en) | 2003-07-23 | 2005-02-03 | Graham Oldfield | Control area selection in a computing device with a graphical user interface |
CN1901911A (zh) | 2003-11-06 | 2007-01-24 | 细胞基因公司 | 使用沙利度胺治疗和控制癌症和其它疾病的组合物和方法 |
US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
US20070135454A1 (en) | 2003-11-14 | 2007-06-14 | Tracy Bayliss | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) |
EP1694328A4 (en) | 2003-12-02 | 2010-02-17 | Celgene Corp | METHOD AND COMPOSITIONS FOR THE TREATMENT AND SUPPLY OF HEMOGLOBINOPATHY AND ANEMIA |
US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
JP2007530544A (ja) | 2004-03-22 | 2007-11-01 | セルジーン・コーポレーション | 皮膚疾患又は障害を治療及び管理するための免疫調節化合物の使用方法及びそれを含む組成物 |
US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
JP2007533761A (ja) | 2004-04-23 | 2007-11-22 | セルジーン・コーポレーション | 肺高血圧症を治療し管理するための、免疫調節性化合物の使用方法及び免疫調節性化合物を含む組成物 |
EP1814543A2 (en) | 2004-11-12 | 2007-08-08 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases |
WO2006058008A1 (en) | 2004-11-23 | 2006-06-01 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
GB0506147D0 (en) | 2005-03-24 | 2005-05-04 | Merck Sharp & Dohme | Therapeutic agents |
CA2607929A1 (en) | 2005-05-11 | 2006-11-16 | Merck Sharp & Dohme Limited | 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1) |
GB0509573D0 (en) | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
US20090163525A1 (en) | 2006-04-05 | 2009-06-25 | Astrazeneca Ab | Substituted quinazolines with anti-cancer activity |
EP2007737A2 (en) | 2006-04-05 | 2008-12-31 | AstraZeneca AB | Chemical compounds |
US20090149484A1 (en) | 2006-04-18 | 2009-06-11 | Astrazeneca Ab | Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them |
DK2428513T3 (en) * | 2006-09-26 | 2017-08-21 | Celgene Corp | 5-substituted quinazolinone derivatives as anti-cancer agents |
CN104211684A (zh) | 2007-09-26 | 2014-12-17 | 细胞基因公司 | 6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法 |
US9095596B2 (en) | 2009-10-15 | 2015-08-04 | Southern Research Institute | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
WO2012027065A2 (en) | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
EP2640189A4 (en) | 2010-11-18 | 2014-03-19 | Deuteria Pharmaceuticals Inc | 3-deutero-pomalidomide |
EP2683384B1 (en) | 2011-03-11 | 2015-12-09 | Celgene Corporation | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
SG192946A1 (en) | 2011-03-11 | 2013-09-30 | Celgene Corp | Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
WO2012149299A2 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
US8901110B2 (en) | 2012-01-13 | 2014-12-02 | Celgene Corporation | Use of biomarkers in methods for the treatment of hepatocellular carcinoma |
ES2699810T3 (es) | 2012-06-29 | 2019-02-12 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando proteínas asociadas a cereblon |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
CN104755472A (zh) | 2012-09-04 | 2015-07-01 | 细胞基因公司 | 3-(5-氨基-2-甲基-4-氧代喹唑啉-3(4h)-基)哌啶-2,6-二酮的同位素体及其制备方法 |
BR112015005243A2 (pt) | 2012-09-10 | 2017-07-04 | Celgene Corp | métodos para o tratamento de câncer de mama localmente avançado |
CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
US9872854B2 (en) | 2013-03-14 | 2018-01-23 | Celgene Corporation | Methods for the treatment of psoriatic arthritis using apremilast |
JP6389241B2 (ja) | 2013-04-17 | 2018-09-12 | シグナル ファーマシューティカルズ,エルエルシー | 癌を治療するためのTORキナーゼ阻害剤及びIMiD化合物を含む組合せ療法 |
AU2014253978B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and a 5-Substituted Quinazolinone Compound for treating cancer |
MX2015014455A (es) | 2013-04-17 | 2016-07-21 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer. |
MX363652B (es) | 2013-05-01 | 2019-03-28 | Celgene Corp | Sintesis de 3-(5-amino-2-metil-4-oxoquinazolin-3(4h)-il)piperidin- 2,6-diona. |
JP2016521280A (ja) | 2013-05-03 | 2016-07-21 | セルジーン コーポレイション | 併用療法を用いて癌を治療する方法 |
CA2932120C (en) | 2013-12-06 | 2023-09-19 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
TW201540323A (zh) | 2014-01-15 | 2015-11-01 | Celgene Corp | 3-(5-胺基-2-甲基-4-側氧基-4h-喹唑啉-3-基)-哌啶-2,6-二酮之調配物 |
WO2015107196A1 (en) | 2014-01-20 | 2015-07-23 | Institut Curie | Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation |
WO2015138902A1 (en) | 2014-03-14 | 2015-09-17 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
KR20210132233A (ko) | 2014-04-14 | 2021-11-03 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법 |
ES2843973T3 (es) | 2014-06-27 | 2021-07-21 | Celgene Corp | Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3 |
JP2017521396A (ja) | 2014-07-11 | 2017-08-03 | セルジーン コーポレイション | 癌のための併用療法 |
WO2016014890A1 (en) | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase |
BR112017002403A2 (pt) | 2014-08-07 | 2017-12-05 | Calithera Biosciences Inc | formas de cristais de inibidores de glutaminase |
WO2016025686A1 (en) | 2014-08-15 | 2016-02-18 | Celgene Corporation | Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition |
JP2017533727A (ja) | 2014-10-13 | 2017-11-16 | セルジーン コーポレイション | 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用 |
WO2016105518A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
WO2016153948A1 (en) | 2015-03-20 | 2016-09-29 | Deuterx, Llc | Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders |
EP3277676B1 (en) | 2015-03-25 | 2023-03-22 | Pierre Fabre Médicament | Substituted quinazoline derivatives as dna methyltransferase inhibitors |
TW201642857A (zh) | 2015-04-06 | 2016-12-16 | 西建公司 | 以組合療法治療肝細胞癌 |
-
2007
- 2007-09-25 DK DK11174059.3T patent/DK2428513T3/en active
- 2007-09-25 PT PT111740593T patent/PT2428513T/pt unknown
- 2007-09-25 HU HUE11174059A patent/HUE035389T2/en unknown
- 2007-09-25 LT LTEP11174059.3T patent/LT2428513T/lt unknown
- 2007-09-25 ES ES11174055.1T patent/ES2564935T3/es active Active
- 2007-09-25 SI SI200731756T patent/SI2420497T1/sl unknown
- 2007-09-25 ES ES11174056.9T patent/ES2633818T3/es active Active
- 2007-09-25 PL PL11174055T patent/PL2420497T3/pl unknown
- 2007-09-25 UA UAA200904043A patent/UA94964C2/ru unknown
- 2007-09-25 EP EP17165492.4A patent/EP3239144A1/en not_active Withdrawn
- 2007-09-25 ES ES07838876T patent/ES2385680T3/es active Active
- 2007-09-25 HU HUE11174056A patent/HUE035308T2/en unknown
- 2007-09-25 LT LTEP11174056.9T patent/LT2420498T/lt unknown
- 2007-09-25 ZA ZA200901950A patent/ZA200901950B/xx unknown
- 2007-09-25 NZ NZ575830A patent/NZ575830A/en unknown
- 2007-09-25 RS RS20160160A patent/RS54607B1/en unknown
- 2007-09-25 KR KR1020097008299A patent/KR101414786B1/ko active IP Right Grant
- 2007-09-25 DK DK07838876.6T patent/DK2066656T3/da active
- 2007-09-25 CN CN201510162174.2A patent/CN105017212A/zh active Pending
- 2007-09-25 MY MYPI20091187 patent/MY150699A/en unknown
- 2007-09-25 ME MEP-2012-60A patent/ME01421B/me unknown
- 2007-09-25 MX MX2009003038A patent/MX2009003038A/es active IP Right Grant
- 2007-09-25 DK DK11174055.1T patent/DK2420497T3/en active
- 2007-09-25 DK DK11174056.9T patent/DK2420498T3/en active
- 2007-09-25 RU RU2009115653/04A patent/RU2463298C2/ru active
- 2007-09-25 CN CNA2007800426159A patent/CN101535291A/zh active Pending
- 2007-09-25 PL PL07838876T patent/PL2066656T3/pl unknown
- 2007-09-25 PL PL11174056T patent/PL2420498T3/pl unknown
- 2007-09-25 ES ES11174059.3T patent/ES2634915T3/es active Active
- 2007-09-25 EP EP11174059.3A patent/EP2428513B1/en active Active
- 2007-09-25 CL CL200702752A patent/CL2007002752A1/es unknown
- 2007-09-25 HU HUE11174055A patent/HUE026827T2/en unknown
- 2007-09-25 ME MEP-2017-152A patent/ME02890B/me unknown
- 2007-09-25 CN CN201510163088.3A patent/CN104910133A/zh active Pending
- 2007-09-25 JP JP2009530406A patent/JP5388854B2/ja not_active Expired - Fee Related
- 2007-09-25 EP EP11174056.9A patent/EP2420498B1/en active Active
- 2007-09-25 ME MEP-2017-159A patent/ME02829B/me unknown
- 2007-09-25 EP EP07838876A patent/EP2066656B1/en active Active
- 2007-09-25 CN CN201710560709.0A patent/CN107445940A/zh active Pending
- 2007-09-25 EP EP11174055.1A patent/EP2420497B1/en active Active
- 2007-09-25 CN CN2012103629552A patent/CN102898416A/zh active Pending
- 2007-09-25 AT AT07838876T patent/ATE555104T1/de active
- 2007-09-25 WO PCT/US2007/020765 patent/WO2008039489A2/en active Application Filing
- 2007-09-25 CA CA2663731A patent/CA2663731C/en not_active Expired - Fee Related
- 2007-09-25 PL PL11174059T patent/PL2428513T3/pl unknown
- 2007-09-25 PT PT111740569T patent/PT2420498T/pt unknown
- 2007-09-25 SI SI200731950T patent/SI2420498T1/sl unknown
- 2007-09-25 SI SI200730915T patent/SI2066656T1/sl unknown
- 2007-09-25 RS RS20170707A patent/RS56279B1/sr unknown
- 2007-09-25 ME MEP-2016-47A patent/ME02420B/me unknown
- 2007-09-25 RS RS20120259A patent/RS52349B/en unknown
- 2007-09-25 PT PT07838876T patent/PT2066656E/pt unknown
- 2007-09-25 CN CN201510163104.9A patent/CN104876908A/zh active Pending
- 2007-09-25 SI SI200731953T patent/SI2428513T1/sl unknown
- 2007-09-26 TW TW102116418A patent/TWI522351B/zh not_active IP Right Cessation
- 2007-09-26 US US11/904,551 patent/US7635700B2/en active Active
- 2007-09-26 PE PE2007001298A patent/PE20080970A1/es active IP Right Grant
- 2007-09-26 AR ARP070104264A patent/AR063015A1/es active IP Right Grant
- 2007-09-26 TW TW096135832A patent/TWI399372B/zh not_active IP Right Cessation
-
2009
- 2009-03-19 IL IL197716A patent/IL197716A/en active IP Right Grant
- 2009-03-25 NI NI200900040A patent/NI200900040A/es unknown
- 2009-04-14 CR CR10712A patent/CR10712A/es unknown
- 2009-04-23 CO CO09041135A patent/CO6160323A2/es unknown
- 2009-12-11 US US12/636,651 patent/US8921385B2/en active Active
-
2012
- 2012-05-24 HR HRP20120447TT patent/HRP20120447T1/hr unknown
- 2012-06-13 CY CY20121100536T patent/CY1112860T1/el unknown
- 2012-06-29 RU RU2012127334A patent/RU2617989C2/ru active
- 2012-08-17 HK HK12108120.2A patent/HK1167397A1/zh not_active IP Right Cessation
-
2013
- 2013-08-18 IL IL228017A patent/IL228017A/en active IP Right Grant
- 2013-10-08 JP JP2013210802A patent/JP5901599B2/ja not_active Expired - Fee Related
-
2014
- 2014-11-24 US US14/552,337 patent/US9732064B2/en active Active
-
2015
- 2015-11-06 JP JP2015218025A patent/JP6133383B2/ja not_active Expired - Fee Related
-
2016
- 2016-03-14 HR HRP20160266TT patent/HRP20160266T1/hr unknown
- 2016-07-12 AR ARP160102114A patent/AR105340A2/es unknown
-
2017
- 2017-02-28 IL IL250847A patent/IL250847A0/en unknown
- 2017-04-18 RU RU2017113360A patent/RU2017113360A/ru not_active Application Discontinuation
- 2017-04-19 JP JP2017082496A patent/JP2017165744A/ja not_active Ceased
- 2017-07-07 US US15/644,119 patent/US20170369471A1/en not_active Abandoned
- 2017-07-17 HR HRP20171093TT patent/HRP20171093T1/hr unknown
- 2017-07-18 HR HRP20171106TT patent/HRP20171106T1/hr unknown
- 2017-07-20 CY CY20171100778T patent/CY1119248T1/el unknown
- 2017-08-02 CY CY20171100831T patent/CY1119176T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171106T1 (hr) | 5-supstituirani kinazolinonski derivati kao sredstva protiv raka | |
JP2016053066A5 (hr) | ||
US11040925B2 (en) | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same | |
CN102264720B (zh) | 用于治疗癌症的异吲哚啉化合物 | |
JP2010505822A5 (hr) | ||
CA2867134C (en) | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds | |
MX2013005434A (es) | 3´ - deutero - polidomida. | |
CN103382197A (zh) | N-甲基氨甲基异吲哚化合物和包含它的组合物及其使用方法 | |
US20100104590A1 (en) | Alpha-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation method and pharmaceutical composition for the immune adjuvant containing the same as an active ingredient | |
CA2681633A1 (en) | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same | |
BRPI1007855B1 (pt) | Formas de dosagem oral compreendendo 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona | |
JP2007508361A5 (hr) | ||
JP2017508795A5 (hr) | ||
JP2013518110A5 (hr) | ||
CN103702665A (zh) | 用于炎症和免疫相关用途的化合物 | |
JP2016520128A5 (hr) | ||
KR20140108707A (ko) | (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제 | |
CA2938198A1 (en) | Heterocyclic sulfonamide derivative and medicine comprising same | |
JP2013525356A5 (hr) | ||
JP2010513551A5 (hr) | ||
JP2012509262A5 (hr) | ||
TW202246218A (zh) | 抗菌化合物 | |
CA2663408A1 (en) | Substituted pyridylmethyl bicyclocarboxyamide compounds | |
RU2019117783A (ru) | Пролекарства пиридонамидов, применяемые в качестве модуляторов натриевых каналов |